当前位置:首页 - 行情中心 - 山河药辅(300452) - 财务分析 - 利润表

山河药辅

(300452)

  

流通市值:24.12亿  总市值:30.27亿
流通股本:1.87亿   总股本:2.34亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入470,839,549.6247,871,756.3882,573,320.58644,353,357.35
  营业收入470,839,549.6247,871,756.3882,573,320.58644,353,357.35
二、营业总成本380,930,612.37200,329,332.3733,237,567.43526,758,558.87
  营业成本318,666,886.64167,658,629.29608,623,452.47436,937,578.94
  税金及附加5,182,848.332,627,748.849,076,050.926,657,365.24
  销售费用14,235,260.597,331,103.9829,409,731.8822,244,761.78
  管理费用15,750,869.077,498,467.5934,848,568.0623,325,121.62
  研发费用22,051,834.8412,333,757.3340,952,648.7628,749,770.86
  财务费用5,042,912.92,879,625.2710,327,115.348,843,960.43
  其中:利息费用6,406,295.583,157,193.9812,732,444.7110,038,238.14
  其中:利息收入643,256.5356,517.76946,672.16882,852.75
三、其他经营收益
  加:公允价值变动收益2,367,019.33-526,013.84-3,134,923.69-6,516,151.13
  加:投资收益6,232,128.162,586,319.419,229,435.5216,898,114.28
  资产处置收益-296,889.16-55,806.89109,338.5-89,632.93
  资产减值损失(新)---39,126,854.84-
  信用减值损失(新)-12,701.9-12,996.672,695.63-59,284.68
  其他收益7,297,880.443,616,786.9116,851,939.5411,700,847.4
四、营业利润105,496,374.153,150,712.91143,267,383.81139,528,691.42
  加:营业外收入213,057.8771,830.8951,646.01482,179.29
  减:营业外支出94,613.4914,627.9963,616.56148,175.69
五、利润总额105,614,818.4853,207,915.9142,355,413.26139,862,695.02
  减:所得税费用12,380,054.936,549,549.6921,830,459.6316,423,782.3
六、净利润93,234,763.5546,658,366.21120,524,953.63123,438,912.72
(一)按经营持续性分类
  持续经营净利润93,234,763.5546,658,366.21120,524,953.63123,438,912.72
(二)按所有权归属分类
  归属于母公司股东的净利润93,035,152.0447,176,895.69119,424,741.26122,425,859.03
  少数股东损益199,611.51-518,529.481,100,212.371,013,053.69
  扣除非经常损益后的净利润84,754,011.3344,631,590.1101,157,550.11104,871,091.88
七、每股收益
  (一)基本每股收益0.40.20.510.53
  (二)稀释每股收益0.380.190.510.52
九、综合收益总额93,234,763.5546,658,366.21120,524,953.63123,438,912.72
  归属于母公司股东的综合收益总额93,035,152.0447,176,895.69119,424,741.26122,425,859.03
  归属于少数股东的综合收益总额199,611.51-518,529.481,100,212.371,013,053.69
公告日期2025-08-272025-04-232025-04-232024-10-23
审计意见(境内)标准无保留意见
TOP↑